US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

271.23

+6.212.34%

Post-market: 271.230.00000.00%19:30 EDT

Volume:37.71K

Turnover:10.15M

Market Cap:2.94B

PE:31.74

High:271.23

Open:268.20

Low:267.24

Close:265.02

52wk High:274.99

52wk Low:173.98

Shares:10.85M

Float Shares:10.85M

Volume Ratio:1.13

T/O Rate:0.35%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:1.06

PE(LYR):7.18

Loading ...

Overview Company News Filings

Corcept Endocrinology President Sean Maduck Disposes of 30,955 Corcept Shares Worth $3.88 Million

Analysts Have Conflicting Sentiments on These Healthcare Companies: NeoGenomics (NEO) and Medtronic (MDT)

NeoGenomics RaDaR ST Gains Expanded Medicare Coverage for Immunotherapy Response Monitoring

Neogenomics Receives Medicare Coverage for Radar St for Immunotherapy Treatment Response Monitoring

THOMSON REUTERS

Circio and Full Circles join forces on non-viral in vivo cell therapy platform

Court Win Over Natera Patents Could Be A Game Changer For NeoGenomics’ (NEO) RaDaR ST

Simply Wall St.

Circio bolsters board as it advances circular RNA gene therapy platform

Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study

The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1

THOMSON REUTERS

Veracyte (VCYT) Receives a Buy from Piper Sandler

Is Bruker’s (BRKR) AI Bet With Atinary Quietly Redefining Its Long-Term R&D Strategy?

Simply Wall St.

Regenxbio reports FDA placed clinical hold on RGX-121

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT)

Corcept Therapeutics Director David L. Mahoney Sells 103,606 Shares Worth $12.26 Million

Patent Cliffs Drive Pharma Expansion as Biotech M&A and IPO Markets Stage a Comeback

Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million

BMO starts Exelixis at Market Perform into patent cliff

Bruker Nano EVP, President Mark Munch Disposes of 4,984 Bruker Shares for $288,636.8

Genprex selects manufacturing organization for diabetes gene therapy

Corcept Therapeutics Incorporated : Truist Securities Assumes Coverage with Buy Rating; Target Price $164 vs $50

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/FBT/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":271.23,"timestamp":1789675200000,"preClose":265.02,"halted":0,"volume":37714,"hourTrading":{"tag":"盘后","latestPrice":271.23,"preClose":271.23,"latestTime":"19:30 EDT","volume":1252,"amount":339578.81,"timestamp":1789687805610,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.023432193796694728,"floatShares":10850002,"shares":10850002,"eps":8.545272,"marketStatus":"Closed","change":6.21,"latestTime":"09-17 16:00:00 EDT","open":268.2,"high":271.23,"low":267.24,"amount":10145857.994,"amplitude":0.015055,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789718400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":265.02,"sharesOutstanding":11450002,"nav":264.91,"aum":2887519529.82,"bidAskSpread":0.00099,"preHourTrading":{"tag":"盘前","latestPrice":265.02,"preClose":265.02,"latestTime":"08:21 EDT","volume":2,"amount":530.04,"timestamp":1789647687231,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":271.23,"preClose":271.23,"latestTime":"19:30 EDT","volume":1252,"amount":339578.81,"timestamp":1789687805610,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.131615,"impliedVol":0.2321,"impliedVolPercentile":0.8127},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10850002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":1.131615,"shares":10850002,"dividePrice":0,"high":271.23,"amplitude":0.015055,"preClose":265.02,"low":267.24,"week52Low":173.975,"pbRate":"1.06","psRate":"709.93","week52High":274.99,"institutionHeld":0,"latestPrice":271.23,"eps":8.545272,"divideRate":0,"volume":37714,"delay":0,"ttmEps":8.545272,"open":268.2,"prevYearClose":206.52,"prevWeekClose":261.85,"prevMonthClose":267.15,"prevQuarterClose":247.89,"fiveDayClose":262.28,"twentyDayClose":271.87,"sixtyDayClose":230.605},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662033320","title":"Corcept Endocrinology President Sean Maduck Disposes of 30,955 Corcept Shares Worth $3.88 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662033320","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662033320?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:31","pubTimestamp":1787862696,"startTime":"0","endTime":"0","summary":"Corcept Endocrinology President Sean Maduck disposes of 30,955 Corcept shares worth $3.88 millionCorcept Therapeutics President, Corcept Endocrinology Sean Maduck exercised stock options for 30,955 co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDLbYdy60:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Endocrinology President Sean Maduck Disposes of 30,955 Corcept Shares Worth $3.88 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","CORT","BK4532","LU1559883803.SGD","LU0566484027.USD","BK4007","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703720","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: NeoGenomics (NEO) and Medtronic (MDT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662703720?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:10","pubTimestamp":1787825408,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NeoGenomics (NEO) and Medtronic (MDT). NeoGenomics...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-neogenomics-neo-and-medtronic-mdt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-neogenomics-neo-and-medtronic-mdt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BVYPNW00.USD","LU1116320737.USD","LU0211326839.USD","XBI","IE00B42XCP33.USD","BK4588","LU0106261372.USD","LU1989764748.USD","LU0128526141.USD","LU2028103732.USD","LU1989771016.USD","LU0029874061.USD","LU1244550577.SGD","IE00BVYPNV92.GBP","LU1571399168.USD","BK4137","LU0012050646.USD","FBT","LU0432979614.USD","LU2023251221.USD","BK4585","LU0211331839.USD","LU1116320901.HKD","LU0006306889.USD","IE00BGHQF631.EUR","LU2089283258.USD","LU0072461881.USD","LABU","LU0162691827.USD","HCSG","LU0158827781.USD","IE000M9KFDE8.USD","LU0208291251.USD","LU0265550359.USD","LU1244550494.USD","LU1983299246.USD","BK4581","LU2089984988.USD","LU0496365809.HKD","NEO","LU1291159041.SGD","LU1989764664.SGD","BK4566","MDT","IE00BQXX3F31.USD","LU1506573853.SGD","IE00B3PB1722.GBP","BK4196","IE00BFXG1179.USD","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662744692","title":"NeoGenomics RaDaR ST Gains Expanded Medicare Coverage for Immunotherapy Response Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2662744692","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662744692?lang=en_us&edition=fundamental","pubTime":"2026-08-27 04:19","pubTimestamp":1787775586,"startTime":"0","endTime":"0","summary":"NeoGenomics RaDaR ST gains expanded Medicare coverage for immunotherapy response monitoringNeoGenomics secured expanded Medicare coverage from CMS MolDX for its RaDaR ST MRD assay to monitor immunothe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL3k3Zl5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NEO","LU0106261612.USD","FBT","LU0012050646.USD","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662744512","title":"Neogenomics Receives Medicare Coverage for Radar St for Immunotherapy Treatment Response Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2662744512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662744512?lang=en_us&edition=fundamental","pubTime":"2026-08-27 04:17","pubTimestamp":1787775420,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nTUA2J4Z9Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0106261612.USD","BK4121","NEO","LU0012050646.USD","FBT","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662760351","title":"Circio and Full Circles join forces on non-viral in vivo cell therapy platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760351","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662760351?lang=en_us&edition=fundamental","pubTime":"2026-08-26 13:43","pubTimestamp":1787723005,"startTime":"0","endTime":"0","summary":"Targovax ASA ( ($GB:0RIS) ) just unveiled an announcement. Circio Holding ASA and Full Circles Therapeutics have entered a research collaboration t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/circio-and-full-circles-join-forces-on-non-viral-in-vivo-cell-therapy-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/circio-and-full-circles-join-forces-on-non-viral-in-vivo-cell-therapy-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","SYNB","TBXU","IBBQ","LFSC","BK4585","IBB","CNCR","BK4588","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662757992","title":"Court Win Over Natera Patents Could Be A Game Changer For NeoGenomics’ (NEO) RaDaR ST","url":"https://stock-news.laohu8.com/highlight/detail?id=2662757992","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662757992?lang=en_us&edition=fundamental","pubTime":"2026-08-26 03:24","pubTimestamp":1787685840,"startTime":"0","endTime":"0","summary":"NeoGenomics, Inc. previously announced that Alicia Olivo, EVP, General Counsel & Business Development, would step down as General Counsel in September 2026 and remain with the company until early October 2026 to support the transition.\nThe company also secured a favorable North Carolina court ruling that invalidated key Natera patents, reducing legal friction around its RaDaR ST assay and altering the competitive landscape in molecular residual disease testing.\nWe’ll now examine how this...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/court-win-over-natera-patents-could-be-a-game-changer-for-ne","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/court-win-over-natera-patents-could-be-a-game-changer-for-ne","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2264538146.SGD","BK4121","NTRA","LU2065171402.SGD","LU1064131342.USD","LU2065731478.USD","LU0053671581.USD","NEO","LU2065170008.USD","FBT","LU2065169927.USD","LU2324357040.USD","LU0963586101.USD","HELX","LU0345770308.USD","LU1988902786.USD","LU0012050646.USD","LU0345770993.USD","BK4139","LU2065171311.SGD","BK4196","GNOM","LU0106261612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662759663","title":"Circio bolsters board as it advances circular RNA gene therapy platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2662759663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662759663?lang=en_us&edition=fundamental","pubTime":"2026-08-26 01:07","pubTimestamp":1787677640,"startTime":"0","endTime":"0","summary":"Targovax ASA ( ($GB:0RIS) ) has issued an announcement. Circio Holding ASA has strengthened its board of directors as it enters a new development p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/circio-bolsters-board-as-it-advances-circular-rna-gene-therapy-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/circio-bolsters-board-as-it-advances-circular-rna-gene-therapy-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LFSC","IE0009354923.USD","CNCR","IBB","BK4585","BK4505","FBT","SYNB","IBBQ","RNA","BK4588","GNOM","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662620199","title":"Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2662620199","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662620199?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:30","pubTimestamp":1787610625,"startTime":"0","endTime":"0","summary":"Alkermes’ alixorexton posts positive Phase 2 Vibrance-1 results in narcolepsy type 1 studyAlkermes reported publication of positive Phase 2 Vibrance-1 results for alixorexton in adults with narcolepsy type 1 in The Lancet Neurology.Results were previously announced, not newly presented, showing improved daytime wakefulness and sleepiness measures versus placebo.Study also indicated reduced cataplexy at one dose, with broader patient-reported benefits in daily functioning.Safety profile appeared generally well tolerated, with mostly mild-to-moderate adverse events and no serious treatment-emergent events reported.Positive Phase 2 readouts supported the launch of the global Phase 3 Brilliance program testing once-daily and split-dose regimens in narcolepsy types 1 and 2.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL56tjq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","PSCH","FBT","IBRN","BK4139","MEDX","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201993","title":"The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201993?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:30","pubTimestamp":1787610600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA7VQ936:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","MEDX","PSCH","FBT","BK4139","IBRN","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271984","title":"Veracyte (VCYT) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271984","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271984?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:15","pubTimestamp":1787577318,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst David Westenberg maintained a Buy rating on Veracyte today and set a price target of $54.00. According to TipRanks, Westenber...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/veracyte-vcyt-receives-a-buy-from-piper-sandler-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/veracyte-vcyt-receives-a-buy-from-piper-sandler-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VCYT","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271451","title":"Is Bruker’s (BRKR) AI Bet With Atinary Quietly Redefining Its Long-Term R&D Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271451","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271451?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:21","pubTimestamp":1787574101,"startTime":"0","endTime":"0","summary":"In August 2026, Bruker’s board declared a quarterly cash dividend of US$0.05 per share, payable on October 7, 2026, to shareholders of record as of September 21, 2026, while the company also expanded its collaboration with Atinary Technologies and took a minority stake in the AI-driven R&D firm. \nThe Atinary collaboration links Bruker’s analytical instruments and SciY software with AI-guided Self-Driving Lab workflows, aiming to automate complex chemical experimentation and generate...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/is-brukers-brkr-ai-bet-with-atinary-quietly-redefining-its-l","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/is-brukers-brkr-ai-bet-with-atinary-quietly-redefining-its-l","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TINY","AGIX","ARTY","LU1815336091.USD","QTOC","AIPO","VTHR","BRKR","FBT","CHAT","LU0757428866.USD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661627309","title":"Regenxbio reports FDA placed clinical hold on RGX-121","url":"https://stock-news.laohu8.com/highlight/detail?id=2661627309","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661627309?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:20","pubTimestamp":1787570406,"startTime":"0","endTime":"0","summary":"Regenxbio (RGNX) provided an update on its investigational gene therapy, RGX-121, for the treatment of Mucopolysaccharidosis type II, also known as...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-reports-fda-placed-clinical-hold-on-rgx-121-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-reports-fda-placed-clinical-hold-on-rgx-121-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","CNCR","FBT","BK4139","BK4585","LABU","GNOM","IBBQ","LFSC","BK4563","IBB","SYNB","RGNX","TBXU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661262741","title":"Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661262741","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661262741?lang=en_us&edition=fundamental","pubTime":"2026-08-21 19:00","pubTimestamp":1787310037,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORT), Alvotech (ALVO) and Abb...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-corcept-therapeutics-cort-alvotech-alvo-and-abbott-laboratories-abt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-corcept-therapeutics-cort-alvotech-alvo-and-abbott-laboratories-abt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0432979614.USD","IE00B4R5TH58.HKD","BK4592","LU2324357040.USD","BK4581","SGXZ41872573.SGD","LABU","LU2133065610.SGD","IHI","XLV","ABT","LU0208291251.USD","LU1914381329.SGD","SG9999002224.SGD","BK4139","BK4082","LU0122379950.USD","FBT","LU0320765489.SGD","HCSG","LU1721429402.USD","LU0029874061.USD","SG9999002232.USD","PJP","LU0058720904.USD","LU0882574055.USD","IE00BFTCPJ56.SGD","TMED","XBI","CORT","LU0211331839.USD","BK4568","LU0070302665.USD","LU0266013472.USD","LU2237957811.SGD","IE0009355771.USD","LU1721429741.USD","BK4007","IE00B2B36J28.USD","LU2112291526.USD","BK4137","LU0566484027.USD","ALVO","PSCH","LU1559883803.SGD","LU0868494617.USD","LU0234572021.USD","LU2237957902.USD","LU1023059063.AUD","LU2211815571.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661129232","title":"Corcept Therapeutics Director David L. Mahoney Sells 103,606 Shares Worth $12.26 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661129232","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661129232?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:30","pubTimestamp":1787257853,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics director David L. Mahoney sells 103,606 shares worth $12.26 millionCorcept director David L. Mahoney sold 103,606 shares on Aug. 18.Sales priced at $117.47 to $119.64, weighted-av","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL759h51:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Therapeutics Director David L. Mahoney Sells 103,606 Shares Worth $12.26 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4007","CORT","LU0566484027.USD","PSCH","LU1559883803.SGD","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184678054","title":"Patent Cliffs Drive Pharma Expansion as Biotech M&A and IPO Markets Stage a Comeback","url":"https://stock-news.laohu8.com/highlight/detail?id=1184678054","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184678054?lang=en_us&edition=fundamental","pubTime":"2026-08-19 16:15","pubTimestamp":1787127336,"startTime":"0","endTime":"0","summary":"Andy Acker, Portfolio Manager for healthcare and biotech strategies at Janus Henderson Investors, notes that despite interest rates remaining higher than markets anticipated at the start of the year,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNX","IYG","BK4588","BIB","IBBJ","MRNY","BBP","BBC","IBB","IJT","BK4585","IAI","BIS","QSML","SPCK","FBT","IWO","BK4582","GTPE","PBE","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660371492","title":"Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660371492","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660371492?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:31","pubTimestamp":1787085063,"startTime":"0","endTime":"0","summary":"Corcept Chief Business Officer Gary Charles Robb sells 10,000 shares for $1.16 millionCorcept Therapeutics Chief Business Officer Gary Charles Robb sold 10,000 common shares on Aug. 17.Sale priced at ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLc47Ccv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4007","CORT","BK4532","LU0566484027.USD","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660492411","title":"BMO starts Exelixis at Market Perform into patent cliff","url":"https://stock-news.laohu8.com/highlight/detail?id=2660492411","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660492411?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:30","pubTimestamp":1787085023,"startTime":"0","endTime":"0","summary":"BMO Capital initiated coverage of Exelixis (EXEL) with a Market Perform rating and $54 price target Exelixis is anchored by cabozantinib, a “durabl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bmo-starts-exelixis-at-market-perform-into-patent-cliff-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bmo-starts-exelixis-at-market-perform-into-patent-cliff-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JDOC","BME","EXEL","IYH","LU2272731865.HKD","PJP","APXH","IE00B5TLWC47.USD","GSKH","SYNB","FHLC","RXL","LU1992135399.USD","BK4207","FXH","IHE","LU2272731782.SGD","BMO","LU2322448791.USD","PBPH","BK4532","BBH","BK4588","RXD","AZNH","CURE","LU2272731600.USD","LU2473716301.USD","IBB","XPH","TRUH","FTXH","PPH","MEDX","LU1992135472.HKD","LU2322448957.HKD","BK4585","USRD","FBT","MEDI","RSPH","BK4139","TMED","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660494087","title":"Bruker Nano EVP, President Mark Munch Disposes of 4,984 Bruker Shares for $288,636.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2660494087","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660494087?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:16","pubTimestamp":1787084184,"startTime":"0","endTime":"0","summary":"Bruker Nano EVP, President Mark Munch disposes of 4,984 Bruker shares for $288,636.8Mark Munch, executive vice president and president of Bruker Nano, reduced his Bruker holdings to 134,806 shares.Sold 2,000 shares on Aug. 14 at USD 57.6 under a 10b5-1 plan.Disposed of 2,984 shares on Aug. 15 at USD 57.7 to cover tax withholding tied to RSU vesting.Exercised options for 2,000 shares on Aug. 14 at USD 22.19.Received 14,443 restricted stock units on Aug. 15 at USD 0.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bruker Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 18, 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL6tynRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bruker Nano EVP, President Mark Munch Disposes of 4,984 Bruker Shares for $288,636.8","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TINY","LU0757428866.USD","FBT","LU1815336091.USD","BRKR","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461015","title":"Genprex selects manufacturing organization for diabetes gene therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461015","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461015?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:10","pubTimestamp":1787051418,"startTime":"0","endTime":"0","summary":"Genprex (GNPX) has entered into a development and manufacturing agreement with a U.S. based clinical and commercial Contract Development and Manufa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genprex-selects-manufacturing-organization-for-diabetes-gene-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genprex-selects-manufacturing-organization-for-diabetes-gene-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","GNOM","GNPX","IBBQ","CNCR","BK4588","FBT","EES","SYNB","TBXU","IBB","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660619704","title":"Corcept Therapeutics Incorporated : Truist Securities Assumes Coverage with Buy Rating; Target Price $164 vs $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2660619704","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660619704?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:04","pubTimestamp":1787051049,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F0P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","LU1559883803.SGD","PSCH","FBT","BK4532","CORT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}